# Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

> **NCT00011414** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 29 (actual)

## Conditions studied

- Wilms' Tumor
- Sarcoma
- Adenaocortical Carcinoma
- Refractory Cancer
- Coldrhood Cancer

## Interventions

- **DRUG:** Tariquidar

## Key facts

- **NCT ID:** NCT00011414
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02-15
- **Primary completion:** 2007-11-28
- **Final completion:** 2016-01-13
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00011414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00011414, "Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00011414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*